Literature DB >> 17059087

[Prevention of hereditary haemoglobinopathies in The Netherlands].

P C Giordano1, C L Harteveld.   

Abstract

Haemoglobinopathies are defects that interfere with the synthesis of haemoglobin. Parents who are both healthy carriers (heterozygotes) may produce severely affected homozygous or compound heterozygous children who can be treated only symptomatically. Offering Dutch couples at risk the possibility of primary prevention is a matter of good healthcare and its organisation deserves priority. The prevention of haemoglobinopathy is based on the provision of information to potential carriers, carrier diagnostics and counselling, services that can in principle be provided by existing public health care institutions. Three moments at which the prevention of recessive diseases can be offered are the phase of preconception, the phase of early pregnancy (prospective primary prevention) and the postnatal phase at the time of a following pregnancy (retrospective primary prevention). By providing basic information and requesting laboratory tests for the diagnosis ofhaemoglobinopathy, the general practitioner plays a crucial role in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059087

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  Screening and genetic diagnosis of hemoglobinopathies in southern and northern europe: two examples.

Authors:  Antonio Amato; Piero C Giordano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-08-08       Impact factor: 2.576

2.  Attitudes of general practitioners and midwives towards ethnicity-based haemoglobinopathy-carrier screening.

Authors:  Suze M P J Jans; Ank de Jonge; Lidewij Henneman; Martina C Cornel; Antoinette L M Lagro-Janssen
Journal:  Eur J Hum Genet       Date:  2012-05-02       Impact factor: 4.246

3.  A case study of haemoglobinopathy screening in the Netherlands: witnessing the past, lessons for the future.

Authors:  Suze M P J Jans; Carla G van El; Eddy S Houwaart; Marjan J Westerman; Rien J P A Janssens; Antoinette L M Lagro-Janssen; Anne Marie C Plass; Martina C Cornel
Journal:  Ethn Health       Date:  2011-08-08       Impact factor: 2.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.